Chow-fed mice with KO of Gipr in GABAergic neurones achieved by crossing Gipr fx/fx with VGAT-Cre strains, were also previously reported to have normal body weight, although with subtle differences in fat mass and respiratory exchange ratio (RER), and improved glucose metabolism 5,11
As a modified peptide analog rather than a full receptor-active growth hormone construct, AOD 9604 is distinguished by its selective interaction with metabolic signaling pathways associated with lipid mobilization rather than canonical GH receptor activation
Food and Drug Administration (FDA) evaluates investigational compounds through a structured review process that typically includes preclinical research, Phase 1, Phase 2, and Phase 3 clinical trials
Skeptics counter that those figures come from voluntary reporting rather than controlled trials, and that questions remain about immunogenicity, whether the body mounts an immune response to the peptide